3,373,000 Shares in Niagen Bioscience, Inc. $NAGE Bought by SteelPeak Wealth LLC

SteelPeak Wealth LLC acquired a new position in Niagen Bioscience, Inc. (NASDAQ:NAGE) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 3,373,000 shares of the company’s stock, valued at approximately $14,875,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Chicago Partners Investment Group LLC bought a new stake in shares of Niagen Bioscience during the 1st quarter valued at $214,000. OP Asset Management Ltd bought a new position in shares of Niagen Bioscience in the 1st quarter worth about $1,475,000. Silverberg Bernstein Capital Management LLC lifted its position in Niagen Bioscience by 5.3% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 138,102 shares of the company’s stock valued at $609,000 after acquiring an additional 6,940 shares during the period. Corient Private Wealth LLC purchased a new position in Niagen Bioscience during the 4th quarter valued at about $200,000. Finally, Invesco Ltd. boosted its stake in Niagen Bioscience by 28.5% during the fourth quarter. Invesco Ltd. now owns 43,641 shares of the company’s stock worth $278,000 after acquiring an additional 9,688 shares in the last quarter. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Wall Street Zen cut shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Freedom Capital upgraded shares of Niagen Bioscience to a “strong-buy” rating in a report on Monday, July 6th. HC Wainwright reissued a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, July 1st. Canaccord Genuity Group cut their price target on Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $10.50.

Niagen Bioscience Stock Down 2.0%

Shares of NAGE opened at $3.40 on Friday. Niagen Bioscience, Inc. has a twelve month low of $3.17 and a twelve month high of $11.58. The company has a market capitalization of $270.78 million, a P/E ratio of 16.19 and a beta of 2.09. The firm has a 50 day moving average of $3.55 and a 200 day moving average of $4.65.

Niagen Bioscience (NASDAQ:NAGE) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. Niagen Bioscience had a return on equity of 22.68% and a net margin of 14.29%.The business had revenue of $31.47 million for the quarter. On average, sell-side analysts expect that Niagen Bioscience, Inc. will post 0.22 EPS for the current year.

Niagen Bioscience Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.